* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
SHSE:600993'
s PEG Ratio Range Over the Past 10 Years
Min: 0.8 Med: 2.95 Max: 6.73
Current: 2.24
During the past 13 years, Mayinglong Pharmaceutical Group Co's highest PEG Ratio was 6.73. The lowest was 0.80. And the median was 2.95.
SHSE:600993's PEG Ratio is ranked worse than 57.76% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.665
vs SHSE:600993: 2.24
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Mayinglong Pharmaceutical Group Co (SHSE:600993) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Mayinglong Pharmaceutical Group Co PEG Ratio Related Terms
Mayinglong Pharmaceutical Group Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayinglong Pharmaceutical Group Co PEG Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Mayinglong Pharmaceutical Group Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayinglong Pharmaceutical Group Co PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mayinglong Pharmaceutical Group Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Mayinglong Pharmaceutical Group Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Mayinglong Pharmaceutical Group Co (SHSE:600993) has a PEG Ratio of 2.24 as of Jul. 12, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Mayinglong Pharmaceutical Group Co and its competitors. This is 24% below median its historical median of 2.95. Over the past decade, Mayinglong Pharmaceutical Group Co's PEG Ratio has ranged from 0.80 to 6.73. According to the industry distribution chart, Mayinglong Pharmaceutical Group Co ranks #201 out of 348 companies in the Drug Manufacturers industry, placing it in the top 57.8%.
Is Mayinglong Pharmaceutical Group Co's PEG Ratio too high?
Mayinglong Pharmaceutical Group Co's current PEG Ratio of 2.24 is 24% below median its 10-year median of 2.95. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 6.73. The Drug Manufacturers industry median PEG Ratio is 1.67. Mayinglong Pharmaceutical Group Co's value of 2.24 is 34.5% above this industry median. Based on the distribution chart, Mayinglong Pharmaceutical Group Co ranks #201 out of 348 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Mayinglong Pharmaceutical Group Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mayinglong Pharmaceutical Group Co's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mayinglong Pharmaceutical Group Co ranks #201 out of 348 companies for PEG Ratio. This places Mayinglong Pharmaceutical Group Co in the lower half of its industry. The industry median PEG Ratio is 1.67. Mayinglong Pharmaceutical Group Co's value of 2.24 is 34.5% above this benchmark. Historically, Mayinglong Pharmaceutical Group Co's own PEG Ratio has ranged from 0.80 to 6.73 over the past decade. While the company's 10-year median is 2.95 vs. the industry median of 1.67, Mayinglong Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.67, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayinglong Pharmaceutical Group Co's current PEG Ratio of 2.24 is 34.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Mayinglong Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayinglong Pharmaceutical Group Co's current PEG Ratio is 2.24, which is 24% below median its own 10-year median of 2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayinglong Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co (SHSE:600993) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥29.53, compared to a current price of ¥23.25 — trading 21.3% below its estimated fair value. The current PEG Ratio is 2.24, which is 24% below median its 10-year median of 2.95 and 34.5% above the Drug Manufacturers industry median of 1.67. Mayinglong Pharmaceutical Group Co's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Mayinglong Pharmaceutical Group Co (SHSE:600993), the current PEG Ratio is 2.24 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayinglong Pharmaceutical Group Co (SHSE:600993) Overvalued in 2026?
Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥23.25 is trading 21.3% below its estimated GF Value™ of ¥29.53.
GuruFocus considers Mayinglong Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:600993:
PEG Ratio: 2.24 (24% below median its 10-year median of 2.95)
GF Value™: ¥29.53 vs. price of ¥23.25 (21.3% below fair value)
Industry Position: 34.5% above the Drug Manufacturers median (#201 of 348)
No single metric tells the full story. See the SHSE:600993 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayinglong Pharmaceutical Group Co Business Description
Mayinglong Pharmaceutical Group Co Ltd is a China-based company mainly involved in pharmaceutical development, retailing and wholesaling. The company provides ointments, suppositories, and tablets for hemorrhoids.
92GF Score
Get the complete analysis for SHSE:600993
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600993 has been successfully added to your 
